Covid-19 roundup: Novavax begins PhII trial in US and Australia; AstraZeneca signs US manufacturing deal with Catalent
Novavax is pushing forward with the Phase II portion of a Phase I/II trial for its vaccine in the US and Australia — this time putting the focus on older patients.
About 50% of participants enrolled in the Phase II portion are between the ages of 60 to 84, according to the US-based company. Novavax recently wrapped up the Phase I portion in Australia, and reported in a preprint that the candidate, NVX-CoV2373, elicited antibody responses greater than those seen in convalescent sera.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.